Publications by authors named "Guillaume Cartron"

Claim this Profile
C
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.
Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Guillaume Cartron

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.
Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant, Maya Hacini, Kamel Laribi, Guillaume Cartron

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
Matthew J Maurer, Vit K Prochazka, Tarec Christoffer El-Galaly, Christopher R Flowers, Diego Villa, Guillaume Cartron

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.
Jean Galtier, Pierre Sesques, Vivien Dupont, Emmanuel Bachy, Roberta Di Blasi, Guillaume Cartron

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.
David Ternant, Olivier Le Tilly, Guillaume Cartron, Céline Desvignes, Amina Bensalem

Clin Pharmacokinet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry.
Federico Erbella, Emmannuel Bachy, Guillaume Cartron, Elodie Gat, Guillaume Manson

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma.
Sara Ovejero, Julie Devin, Laura Alibert, Camille Soun, Yea-Lih Lin, Guillaume Cartron

Hematol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Bispecific antibodies: indications and perspectives in onco-hematology].
Léa Fornero, Guillaume Cartron

Rev Prat· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.
Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, Emmanuel Itti, Pierre Feugier, Guillaume Cartron

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study.
Solène Malmon, Olivier Casasnovas, Marguerite Fournier, Guillaume Cartron, Salim Kanoun

Eur J Nucl Med Mol Imaging· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.
Guillaume Cartron, Roch Houot, Yassine Al Tabaa, Fabien Le Bras, Loïc Ysebaert

Nat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Guillaume Cartron

Br J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells.
Michaël Constantinides, Loïs Coënon, Paolo Falvo, Caroline Multrier, Davide Lombardi, Guillaume Cartron

MedComm (2020)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting SUMOylation triggers interferon-ß-dependent activation of patient and allogenic Natural Killer cells in preclinical models of Acute Myeloid Leukemia.
Rawan Hallal, Marion de Toledo, Denis Tempé, Rayane Berrahouane, Sara Zemiti, Guillaume Cartron

Mol Cancer Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
Arnon P Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Guillaume Cartron

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.
Vincent Camus, Thierry Molina, Fabienne Desmots, Paul Blanc-Durand, Salim Kanoun, Guillaume Cartron

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.
Pablo Mozas, Romain Ould Ammar, Loïc Chartier, Loretta Nastoupil, Emmanuel Bachy, Guillaume Cartron

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.
Sara Ovejero, Laura Alibert, Julie Devin, Tatiana Cañeque, Valentin Jacquier, Guillaume Cartron

Theranostics· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.
Laure Dutrieux, Sara Ovejero, Antoine Guillemin, Miss Leriem Zellagui, Elke De Bruyne, Guillaume Cartron

Blood Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma.
Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Guillaume Cartron

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.
Jean Galtier, Charles Mesguich, Pierre Sesques, Vivien Dupont, Emmanuel Bachy, Guillaume Cartron

Hemasphere· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.
Amira Marouf, Sammara Chaubard, Raphaël Liévin, Jean-Marie Michot, Nicolas Molinari, Guillaume Cartron

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)].
Guillaume Cartron, Catherine Thieblemont, Isabelle Borget, Catherine Rioufol, Margaux Berthet

Bull Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).
Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, Kamal Bouabdallah, Mathieu Leclerc, Guillaume Cartron

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F158V alleles frequency differs in multiple myeloma patients from healthy population.
Michaël Constantinides, Nicolas Robert, Caroline Multrier, Loïs Coënon, Mauricio Campos-Mora, Guillaume Cartron

Oncoimmunology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis